Company Overview
About Phlow
Phlow is a public benefit pharmaceutical company that develops and manufactures critical active pharmaceutical ingredients (APIs) and finished dosage forms entirely within the United States. Its mission is to strengthen national medicine supply chains by producing drugs domestically, reducing dependence on foreign API suppliers — primarily in China and India — that supply the majority of the U.S. medicine supply. Phlow''s manufacturing model uses continuous flow chemistry and advanced automation to produce APIs at lower cost and higher quality consistency than traditional batch manufacturing.
Business Model & Competitive Advantage
The company raised $37M in a Series C round in July 2025, led by Align Private Capital LLC, bringing total private capital raised to over $93M. Alongside private funding, Phlow has been awarded more than $600M in government contracts, including a $354M contract from HHS/ASPR/BARDA to manufacture essential medicines in shortage. The FDA Commissioner selected Phlow for its first-ever National Priority Voucher Pilot Program to advance domestic manufacturing of critical essential medicines in 2025.
Competitive Landscape 2025–2026
Phlow serves as a critical node in U.S. health security infrastructure, manufacturing APIs and finished dosage forms across cardiovascular, pain and sedation, respiratory, antiemetic, antibacterial, and anticholinergic therapeutic categories. Its strategic importance is reinforced by bipartisan policy support for domestic pharmaceutical manufacturing as a national security priority. Phlow competes indirectly with foreign API manufacturers and domestic CDMOs like Pfizer CentreOne and Catalent, but its public benefit mission and government contract base give it a unique market position.
Key Differentiators
Strong Challenger
Phlow is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Compare Phlow with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Phlow? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Phlow Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Phlow vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →